 |
DNDN
RT @BiotechStockRsr: No adverse impact on $DNDN Provenge from the $AMGN denosumab news, by the way. Products are complimentary .
DNDN
No adverse impact on $DNDN Provenge from the $AMGN denosumab news, by the way. Products are complimentary and not competitive.
DNDN
@DogDayAftern00n $dndn is the only drug that will help, FDA at it's best!
DNDN
@cacacemike What's right to you and me ain't always right to the statistical lunatics at the FDA $DNDN
DNDN
$dndn approval a must! It's only right!
DNDN
Update on $MDVN $JNJ $DNDN prostate cancer drugs http://bit.ly/ccucjw
DNDN
@DogDayAftern00n $bcrx $dndn $appl $dndn $seed I want my mommy how can you have any pudding if you don't eat your meat!"
"You! Yes
DNDN
@bearcharts $DNDN Read that article. Many flaws in it. SeekingAlpha sucks anyways. Glad you got calls - smart man.
DNDN
Got completely stopped out of $DNDN today. Unfortunately, I wish I got stopped on some other ones too. :( $YGE $AMZN $GOOG $TNA $TYH
DNDN
@bearcharts FYI I think you're nuts for holding a stock like $DNDN overnight. FDA approval could come at any time.
DNDN
long $DNDN @ 29.46, might sell Feb 30 or 31 calls later
DNDN
sold balance $DNDN calls +.10 refust to let it turn into loser
DNDN
sold half $DNDN calls +.32 just in case it gets dragged further by market
DNDN
$$ Some charts to keep an eye on tomorrow http://bit.ly/cv6FRA $DNDN, $SPR, $JLL
DNDN
Third time $DNDN closed at or within a penny of 30.42. Putting a hard stop for 1/2 at 30, 1/4 at 29.50, and 1/4 at 5% stop-loss.
DNDN
$DNDN, $MCD just name a few, made new high, they made into hint list two days ago. All big moves start with a hint day.http://bit.ly/agb9MJ
DNDN
3 fantastic days for $DNDN. Please do yourself a favor & investigate Dendreon, then invest your money. Get in now, huge upside still ahe
DNDN
RT @SellPuts: $DNDN is one if not the most volatile stocks out there.. she will take u out back and whip you <- Yup I got marks on my bac
DNDN
@desolacapital $DNDN is one if not the most volatile stocks out there.. maybe $RMBS is a second.. she will take u out back and whip you
DNDN
Someone is hiding their offer size at that 30.50 level in $DNDN, shook me out...
DNDN
$DNDN chart .. great 3 day trend. http://chart.ly/5x3a39 .. nice trade @alphatrends
DNDN
all time closing high in $DNDN 30.36
DNDN
@alphatrends nice ... You own $DNDN ...always have
DNDN
doing very little today, $DNDN holds up very well and staying above 30 could set it up for bigger breakout, i'm long calls
DNDN
$DNDN announced webcast presentation @12th Bio CEO and investor conference. Tues 2/9 @ 2pm $30!!
Dendreon Corp. - DNDN Insiders
No Insiders
We have no insiders for Dendreon right now.
Know someone who is an insider on Dendreon Corp.?
Let us know.
Dendreon Corp. - DNDN information
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics that harness the immune system to fight cancer. The company’s product portfolio includes active cellular immunotherapy, monoclonal antibodies, and small molecules products candidates to treat a range of cancers. Its product candidate include Provenge (sipuleucel-T), an active cellular immunotherapy that has completed 2 Phase III clinical trials for the treatment of asymptomatic, metastatic, and androgen-independent prostate cancer; Neuvenge (lapuleucel-T), which has completed phase 1 clinical trials for the treatment of breast, ovarian, and colon cancers. The comp......
www.dendreon.com
484 Employees
Founded in 1992
DENDREON CORP (DNDN:NASDAQ)
LAST $36.50 USD
CHANGE TODAY +1.07 3.02%
VOLUME 3.2M
As of 1:36 PM 03/9/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of DENDREON CORP (DNDN)
|
OPEN
$35.16
|
PREVIOUS CLOSE
$35.43
|
|
|
DAY HIGH
$36.86
|
DAY LOW
$35.16
|
|
|
52 WEEK HIGH
03/9/10 - $36.86
|
52 WEEK LOW
03/9/09 - $2.55
|
|
|
MARKET CAP
4.9B
|
AVERAGE VOLUME 10 D
6.3M
|
|
|
EPS TTM
$-1.29
|
SHARES OUTSTANDING
134.1M
|
|
|
DNDN Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Stock Picks: Disney, PetSmart, Dendreon, Take-Two
03/04/2010 12:07 PM ET
Stocks Finish Higher after Fed Decision
04/29/2009 4:30 PM ET
Analyst Picks and Pans: Dendreon (DNDN), VF Corp. (VFC)
04/29/2009 10:08 AM ET
Dendreon's Prostate Vaccine Validated with Drama
04/28/2009 5:11 PM ET
related news
Dendreon shares climb on Provenge study results
AP Digital - 03/04/2010 1:18 PM ET
Key developments for DENDREON CORP (DNDN)
Dendreon Corp. expected to Report Q1 2010 Results on May 7, 2010. This event was calculated by Capital IQ (Created on February 22, 2010).
02/22/2010
Dendreon Corp. expected to Report Q1 2010 Results on May 7, 2010. This event was calculated by Capital IQ (Created on February 22, 2010).
Dendreon Corp. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2009
02/22/2010
Dendreon Corp. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2009. For the quarter, the company reported net loss was $32.5 million or 0.28 cents loss per basic and diluted share on revenue of $21,000 against net loss of $8.8 million or 0.09 cents loss per basic and diluted share on revenue of $28,000 for the same period last year. Loss from operation was $36.4 million against $15.5 million for the same period last year. For the year, the company reported net loss was $220.2 million or 2.04 cents loss per basic and diluted share on revenue of $101,000 against net loss of $71.6 million or 0.79 cents loss per basic and diluted share on revenue of $111,000 for the same period last year. Loss from operation was $100.0 million against $70.5 million for the same period last year. This loss includes a non-cash fair value adjustment of $118.8 million or $1.10 per share associated with a change in the fair value of warrants.
Dendreon Corp., Q4 2009 Earnings Call, Feb-22-2010
02/11/2010
Dendreon Corp., Q4 2009 Earnings Call, Feb-22-2010
DNDN Competitors
| Company | Last | Change |
| Advaxis Inc | $0.17 USD | 0.00 |
| Antigenics Inc | $0.77 USD | +0.0198 |
| Avax Technologies Inc | $0.09 USD | 0.00 |
| Generex Biotechnology Corp | $0.63 USD | -0.0171 |
| Vical Inc | $3.97 USD | +0.12 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | DNDN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 40,977.4x |
|
| Price/Book | 9.1x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 40,663.3x |
|
|
DNDN |
||
|
DNDN transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
Dendreon Corp. - DNDN news
Buzz on the Street: S&P Climbs Wall of Worry
2010-03-09 07:22:12
Keywords: buzz,banter,trading,investing,markets,analysis,money,finance,BUSINESS & MARKETS ,AMZN,GS,IFF,DNDN,SNY
Quote: Look to potentially add to the position through the $43.00 whole number DailyClick to enlarge60 minClick to enlargeThursday, March 4, 2010Provenge data excellentDavid MillerLate yesterday, Dendreon DNDN) released part of the data that will be presented Friday at the ASCO GU conference in San Francisco. These are updated data on Provenge, the company's drug for prostate cancer. The bottom line is the data got better with age, which is one more positive for the story. It makes even more likely the...Read article
Dendreon shares climb on Provenge study results
2010-03-05 05:27:48
Quote: NEW YORK (AP) -- Shares of Dendreon Corp. rose Thursday as updated study results suggested the drug developer's prostate cancer drug candidate Provenge will likely gain approval in spring and could become a blockbuster treatment.Food and Drug Administration is expected to make a regulatory decision on the drug on May 1.Shares rose $1.54, or 4.6 percent, to $35.16 in midday trading. The stock earlier traded at $35.32, its highest price in a decade. The stock is up 13 percent so far this week.The ...Read article
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
2010-03-04 06:49:13
Quote: ETThe presentations will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com. Â Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Â ...Read article
Sanofi drug shows promise against prostate cancer
2010-03-04 06:49:12
Quote: These can lead to unnecessary biopsies and treatments that do more harm than good, says the society, which recommends that men talk with their doctors about whether screening is wise.Besides the experimental chemo drug, another potential treatment is on the horizon for advanced prostate cancer: Dendreon Corp.'s Provenge vaccine, which trains the immune system to fight tumors. It's called a vaccine even though it treats disease rather than prevents it.http://www.asco.orghttp://www.cancer.net......Read article
Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
2010-03-04 06:49:12
Quote: "Furthermore, the results of this study validate cancer immunotherapy as an entirely new treatment paradigm that can provide patients with a clinically meaningful survival benefit coupled with a well-tolerated safety profile."Dendreon is seeking licensure for PROVENGE for men with metastatic CRPC and submitted an amended Biologics License Application for PROVENGE, for which the U.S. Food and Drug Administration assigned a Prescription Drug User Fee Act date of May 1, 2010.IMPACT Study Detail IMP...Read article
UPDATE - Dendreon: Provenge boosts survival 40 pct
2010-03-04 06:49:11
Keywords: United States of America,Pharmaceuticals (sub-industry),Biotechnology,Healthcare,Company News item,Economic news, EC, business/financial pages,
Quote: UPDATE 3-Dendreon: Provenge boosts survival 40 pct
* Provenge extends 3-yr survival by 40 pct vs placebo * Shares rise 2.9 percent after hours(Adds trial detail, sales projection, updates share price,
paragraphs 2-4, 7) By Deena Beasley LOS ANGELES, March 3 (Reuters) - Updated trial results show
that an experimental cancer vaccine developed by Dendreon Corp
(DNDN.O) improved three-year survival of patients with advanced
prostate cancer by 40 percent compared with a placebo. Dendreon shares rose...Read article
No Panel For Provenge
2010-03-03 02:00:26
Keywords: Medicine, Pharmacuticals, Health Care, Drugs, Drug Companies, Hospitals, Health Insurance
Quote: The experimental prostate cancer treatment Provenge will not face a second panel of experts before the Food and Drug Administration decides whether or not to approve it.
"We will not be having an advisory committee on Provenge," says FDA spokeswoman Karen Riley.
A positive vote from an FDA advisory panel in March 2007 caused shares in maker Dendreon to triple; the stock plummeted three months later after the FDA rejected the drug. Since then, a group called Care To Live, which was foun...Read article
Report Claims Dendreon Facing FDA Panel: BioBuzz
2010-03-03 02:00:26
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Adam Feuerstein ,Drugs
Quote: (Updated with new lede, company, analyst and FDA comments, stock price.)TheStreet) -- Volatility rocked DendreonDNDN Quote) shares Tuesday morning after an independent and unconfirmed research report claimed that the U.S. Food and Drug Administration was going to convene an advisory panel meeting to review the company's prostate cancer drug Provenge.Dendreon shares fell about 10% to below $30 a share in pre-market trading as copies of the bearish report from Favus Institutional Research hit Wall...Read article
Dendreon Won't Face Second FDA Panel: BioBuzz
2010-03-03 02:00:26
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Adam Feuerstein ,Drugs
Quote: (Updated with new lede, company, analyst and FDA comments, stock price.)TheStreet) -- Volatility rocked DendreonDNDN Quote) shares Tuesday morning after an independent and unconfirmed research report claimed that the U.S. Food and Drug Administration was going to convene an advisory panel meeting to review the company's prostate cancer drug Provenge.Dendreon shares fell about 10% to below $30 a share in pre-market trading as copies of the bearish report from Favus Institutional Research hit Wall...Read article
UPDATE - US FDA sees no public hearing for Dendreon vaccine
2010-03-03 02:00:25
Keywords: Pharmaceuticals (sub-industry),United States of America,Washington / US Government News,Regulation and enforcement,Health and medicine,Biotechnology,Healthcare,General News,Politics International Affairs and Law,Domestic Politics,Business activities,Natur
Quote: UPDATE 3-US FDA sees no public hearing for Dendreon vaccine
* No advisory meeting planned, FDA spokeswoman says * Dendreon shares close up 2.3 percent(Updates shares; adds background on previous panel meeting)Susan Heavey WASHINGTON, March 2 (Reuters) - The U.S. Food and Drug
Administration is not planning to seek advice from its outside
advisers over Dendreon Corp's (DNDN.O) experimental prostate
cancer vaccine, fueling investor speculation about the product
and sending company shares higher. ...Read article
Dendreon rises; FDA says no meeting on Provenge
2010-03-03 02:00:25
Quote: WASHINGTON (AP) -- Shares of biotechnology company Dendreon Corp. jumped Tuesday after federal regulators said they don't plan to hold a public meeting on the company's prostate cancer treatment, possibly leading to quicker approval for the drug.Shares of the Seattle-based company rose 70 cents, or 2.1 percent, to $33.21 in afternoon trading. They earlier set a new year high of $35.27, eclipsing a previous peak of $33.85 set Feb. 22.A spokeswoman for the Food and Drug Administration said the age...Read article
Three Biotech Bets Worth Making
2010-03-02 04:19:46
Keywords: Intelligent Investing, Hilary Kramer, Dendreon, Medivation, PositiveID
Quote: del.icio.usDigg It!yahooFacebookTwitterRedditrss
Dendreon Corporation(DNDN -news-people): Currently hovering in the $30-$32 range, this stock could more than double to $65 by mid-2011. The Seattle-based biotech company is focused on targeting and eradicating cancer. This is a revolutionary new way to fight cancer. The key is that DNDN's scientists are on the forefront of introducing a new class of therapy known as active cellular immunotherapies ("ACIs"). This approach uses live human cells to t...Read article
Biotech Calendar: Key Dates for March
2010-03-01 09:11:37
Keywords: Financial, News, Stock, Market, Headlines, Investments, Quotes, Trading, TheStreet.com, Adam Feuerstein ,Drugs
Quote: BOSTON (TheStreet) -- A calendar of important, potentially stock-moving biotech events for March:March 2-3RBC Capital Markets Healthcare ConferenceMarch 4Bristol-Myers Squibb investor/analyst meetingBMY Quote)March 5-7ASCO Genitourinary Cancers Symposium: DendreonDNDN Quote) presenting updated data from the phase III study of ProvengeMarch 8-11Cowen & Co Healthcare ConferenceMarch 9FDA advisory panel meets to discuss InterMune'sITMN Quote) pirfenidone for the treatment of idiopathic pulmonary fi...Read article
Dendreon takes bigger 4Q loss as spending grows
2010-02-26 11:00:31
Quote: SEATTLE (AP) -- Development stage biotechnology company Dendreon Corp. reported a larger fourth-quarter loss on Monday, saying its spending surged as it prepared to file for regulatory approval of its prostate cancer drug Provenge.Dendreon completed its filing for Food and Drug Administration approval in November.The company posted a fourth-quarter loss of $32.5 million, or 28 cents per share. In the fourth quarter of 2008 it took a loss of $8.8 million, or 9 cents per share. Its revenue fell to...Read article
Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
2010-02-25 04:25:53
Quote: Dendreon's total operating expenses for the year ended December 31, 2009 were $100.1 million compared to $70.6 million in 2008. As of December 31, 2009, Dendreon had approximately $606 million in cash, cash equivalents, and short-term and long-term investments compared to $111 million as of December 31, 2008.Recent Highlights: "The positive results from our IMPACT study of PROVENGE made 2009 a momentous year for Dendreon and its stockholders as we initiated the transition to a commercial enterpr...Read article
Dendreon takes bigger 4Q loss as spending grows
2010-02-25 04:25:52
Quote: SEATTLE (AP) -- Development stage biotechnology company Dendreon Corp. reported a larger fourth-quarter loss on Monday, saying its spending surged as it prepared to file for regulatory approval of its prostate cancer drug Provenge.Dendreon completed its filing for Food and Drug Administration approval in November.The company posted a fourth-quarter loss of $32.5 million, or 28 cents per share. In the fourth quarter of 2008 it took a loss of $8.8 million, or 9 cents per share. Its revenue fell to...Read article
Endo Smokin' After Surprising Earnings
2010-02-23 05:00:08
Keywords: U.S. Markets, U.S. Equities, Endo Pharmaceuticals, Pharmaceuticals, Health Care, Prescription drugs, Earnings
Quote: Of particular note were sales of Lidoderm, a topical pain treatment, which accounted for $204 million in the quarter, ahead of the analyst's expected $201 million.Meanwhile, shares of cancer treatment maker DendreonDNDNnewspeople) hit a one-year high on Monday after a JPMorgan Chase analyst started coverage of the company at an "overweight" rating. Dendreon ticked up 58 cents, or 1.8%, to $32.92.Other pharmaceutical makers were trading relatively flat.PfizerPFEnewspeople) ticked up 1 cent, or .1...Read article
Endo Pharma Gains On 2010 Outlook.
2010-02-23 05:00:08
Keywords: U.S. Markets, U.S. Equities, Endo Pharmaceuticals, Pharmaceuticals, Health care, Earnings, Guidance
Quote: Meanwhile, shares of cancer treatment maker DendreonDNDNnewspeople) hit a one-year high on Monday after a JPMorgan Chase analyst started coverage of the company at an "overweight" rating. Dendreon ticked up 95 cents, or 2.9%, to $33.31.Other pharmaceutical makers were trading relatively flat. PfizerPFEnewspeople) ticked up 2 cent, or .1%, to $18.01; Johnson & JohnsonJNJnewspeople) dipped 10 cents, or .2%, to $63.70; and NovartisNVSnewspeople) slid 24 cents, or .4%, to $55.02.......Read article
DENDREON CORP Files SEC form 8-K, Results of Operations and Financial Condition
2010-02-23 05:00:07
Quote: Results of Operations and Financial Condition.
On February 22, 2010, Dendreon Corporation, a Delaware corporation
("Dendreon") issued a press release regarding Dendreon's financial results for
its full year and fourth quarter ended December 31, 2009. The full text of
Dendreon's press release is attached hereto as Exhibit 99.1.
The information in this report, including the exhibit, is provided under Item
2.02 of Form 8-K and, pursuant to General Instruction B.2 of Form 8-K, shall not...Read article
Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
2010-02-23 05:00:07
Quote: Dendreon's total operating expenses for the year ended December 31, 2009 were $100.1 million compared to $70.6 million in 2008. As of December 31, 2009, Dendreon had approximately $606 million in cash, cash equivalents, and short-term and long-term investments compared to $111 million as of December 31, 2008.Recent Highlights: "The positive results from our IMPACT study of PROVENGE made 2009 a momentous year for Dendreon and its stockholders as we initiated the transition to a commercial enterpr...Read article